Skip to main content
Top
Published in: Trials 1/2022

01-12-2022 | Budesonide | Study protocol

Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial

Authors: Qing Kong, Yuxue Cao, Zhen Gao, Jing Sun, Hongying Zhang, Yijie Du, Yubao Lv, Sihan Zhou, Zihui Tang, Baojun Liu, Jingcheng Dong

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Inhaled glucocorticoid corticosteroid (ICS), long-acting β2-adrenoceptor agonist (LABA), and other drugs have limited therapeutic effects on COPD with significant individual differences. Traditional Chinese medicine (TCM)-modified Bushen Yiqi formula (MBYF) demonstrates advantages in COPD management in China. This study aims to evaluate the efficacy and safety of MBYF as an add-on to budesonide/formoterol in COPD patients and confirm the related genes affecting the therapeutic effect in the treatment of COPD.

Methods

In this multicentre, randomised, double-blind, placebo-controlled, parallel-group study, eligible patients with COPD will randomly receive a 360-day placebo or MBYF as an adjuvant to budesonide/formoterol in a 1:1 ratio and be followed up with every 2 months. The primary outcomes will be the frequency, times, and severity of acute exacerbation of COPD (AECOPD), COPD assessment test (CAT) score, and pulmonary function tests (PFTs). The secondary outcomes will include the modified Medical Research Council (mMRC) dyspnoea scale, 6-min walking test (6MWT), BODE index, quantitative scores of syndromes classified in TCM, inflammation indices, and hypothalamic-pituitary-adrenaline (HPA) axis function. We will also test the genotype to determine the relationship between drugs and efficacy. All the data will be recorded in case report forms (CRFs) and analysed by SPSS V.20.0.

Discussion

A randomized clinical trial design to evaluate the efficacy and safety of MBYF in COPD is described. The results will provide evidence for the combination therapy of modern medicine and TCM medicine, and individual therapy for COPD.Trial registration.

Trial registration

ID: ChiCTR1900026124​, Prospective registration.
Appendix
Available only for authorised users
Literature
8.
go back to reference Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):Itc17–itc32.CrossRefPubMed Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):Itc17–itc32.CrossRefPubMed
15.
go back to reference Leitao Filho FS, Takiguchi H, Akata K, Ra SW, Moon JY, Kim HK, et al. Effects of inhaled corticosteroid/long-acting β(2)-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease: a Randomized Controlled Clinical Trial (DISARM). Am J Respir Crit Care Med. 2021;204(10):1143–52. https://doi.org/10.1164/rccm.202102-0289OC.CrossRefPubMed Leitao Filho FS, Takiguchi H, Akata K, Ra SW, Moon JY, Kim HK, et al. Effects of inhaled corticosteroid/long-acting β(2)-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease: a Randomized Controlled Clinical Trial (DISARM). Am J Respir Crit Care Med. 2021;204(10):1143–52. https://​doi.​org/​10.​1164/​rccm.​202102-0289OC.CrossRefPubMed
17.
go back to reference Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe. Eur Respir J. 2018;52(6):1801219.CrossRefPubMed Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe. Eur Respir J. 2018;52(6):1801219.CrossRefPubMed
26.
go back to reference Wang Y, Xu A. Zheng: A systems biology approach to diagnosis and treatments. Science. 2014;346(6216):S13–S5. Wang Y, Xu A. Zheng: A systems biology approach to diagnosis and treatments. Science. 2014;346(6216):S13–S5.
27.
go back to reference Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting aging pathways in chronic obstructive pulmonary disease. Int J Mol Sci. 2020;21(18):6924.CrossRefPubMedCentral Easter M, Bollenbecker S, Barnes JW, Krick S. Targeting aging pathways in chronic obstructive pulmonary disease. Int J Mol Sci. 2020;21(18):6924.CrossRefPubMedCentral
28.
go back to reference Wang GF, Liu BJ, Cao YX, Du YJ, Zhang HY, Luo QL, et al. Effects of two Chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicenter, double-blind, randomized controlled trial. Plos ONE. 2014;9(8):e103168.CrossRefPubMedPubMedCentral Wang GF, Liu BJ, Cao YX, Du YJ, Zhang HY, Luo QL, et al. Effects of two Chinese herbal formulae for the treatment of moderate to severe stable chronic obstructive pulmonary disease: a multicenter, double-blind, randomized controlled trial. Plos ONE. 2014;9(8):e103168.CrossRefPubMedPubMedCentral
32.
go back to reference Wei Y, Lyu Y, Li M, Luo Q, Sun J, Liu F, et al. Comparison of effect of granules and herbs of Bu-Shen-Yi-Qi-Tang on airway inflammation in asthmatic mice. Chin Med J. 2014;127(22):3957–62.PubMed Wei Y, Lyu Y, Li M, Luo Q, Sun J, Liu F, et al. Comparison of effect of granules and herbs of Bu-Shen-Yi-Qi-Tang on airway inflammation in asthmatic mice. Chin Med J. 2014;127(22):3957–62.PubMed
40.
go back to reference Wang GF, Mohammadtursun N, Lv YB, Zhang HY, Sun J, Dong JC. Baicalin exerts anti-airway inflammation and anti-remodelling effects in severe stage rat model of chronic obstructive pulmonary disease. Evid Based Complement Altern Med. 2018;2018:7591348. Wang GF, Mohammadtursun N, Lv YB, Zhang HY, Sun J, Dong JC. Baicalin exerts anti-airway inflammation and anti-remodelling effects in severe stage rat model of chronic obstructive pulmonary disease. Evid Based Complement Altern Med. 2018;2018:7591348.
41.
go back to reference MH L, AH L, HF L, HK K, TS L, YR K. Paeonol attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling. Mediat Inflamm. 2014;2014:651890. MH L, AH L, HF L, HK K, TS L, YR K. Paeonol attenuates cigarette smoke-induced lung inflammation by inhibiting ROS-sensitive inflammatory signaling. Mediat Inflamm. 2014;2014:651890.
42.
go back to reference Lin JP, Xu F, Wang GF, Kong LW, Luo QL, Lv YB, et al. Paeoniflorin attenuated oxidative stress in rat COPD model induced by cigarette smoke. Evid Based Complement Altern Med. 2016;2016:1698379. Lin JP, Xu F, Wang GF, Kong LW, Luo QL, Lv YB, et al. Paeoniflorin attenuated oxidative stress in rat COPD model induced by cigarette smoke. Evid Based Complement Altern Med. 2016;2016:1698379.
43.
go back to reference König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine. Eur Respir J. 2017;50(4). König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine. Eur Respir J. 2017;50(4).
44.
go back to reference Sisodiya SM. Precision medicine and therapies of the future. Epilepsia. 2021;62(Suppl 2):S90–s105.PubMed Sisodiya SM. Precision medicine and therapies of the future. Epilepsia. 2021;62(Suppl 2):S90–s105.PubMed
45.
go back to reference Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2)1900651. Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54(2)1900651.
50.
go back to reference Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (London, England). 2004;364(9444):1505–12.CrossRef Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (London, England). 2004;364(9444):1505–12.CrossRef
56.
go back to reference Vickerstaff V, Ambler G, King M, Nazareth I, Omar RZ. Are multiple primary outcomes analysed appropriately in randomised controlled trials? A review. Contemp Clin Trials. 2015;45(Pt A):8–12.CrossRefPubMed Vickerstaff V, Ambler G, King M, Nazareth I, Omar RZ. Are multiple primary outcomes analysed appropriately in randomised controlled trials? A review. Contemp Clin Trials. 2015;45(Pt A):8–12.CrossRefPubMed
Metadata
Title
Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial
Authors
Qing Kong
Yuxue Cao
Zhen Gao
Jing Sun
Hongying Zhang
Yijie Du
Yubao Lv
Sihan Zhou
Zihui Tang
Baojun Liu
Jingcheng Dong
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06057-7

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue